Top Chinese Whole-Body PET/CT Imaging System Brands for 2026: A B2B Procurement Guide for European and Global Buyers

As the global medical imaging market evolves, Chinese whole-body PET/CT imaging systems have gained significant traction among European and international buyers seeking cost-effective yet technologically advanced solutions. By 2026, several domestic manufacturers are expected to solidify their positions as reliable suppliers, offering systems that rival established Western brands like Siemens Healthineers, GE Healthcare, and Canon Medical in terms of performance, while providing competitive pricing and flexible service models. For B2B procurement professionals, understanding which Chinese brands lead the market and how to navigate the associated technical, regulatory, and logistical challenges is critical to making informed purchasing decisions.

Among the top Chinese PET/CT manufacturers, United Imaging (联影医疗) stands out as a global leader, with its uMI series widely deployed in hospitals across Europe, Asia, and Africa. United Imaging has invested heavily in R&D, achieving CE marking and FDA clearance for its whole-body PET/CT systems, which feature digital silicon photomultiplier (SiPM) technology and AI-assisted reconstruction. Neusoft Medical (东软医疗) is another key player, offering the NeuWise series with time-of-flight (TOF) capabilities and integrated workflow solutions. Anke Medical (安科医疗), though smaller, provides cost-competitive systems suitable for regional hospitals and diagnostic centers. These brands have demonstrated compliance with ISO 13485 and EU MDR (Medical Device Regulation), making them viable options for European buyers. However, procurement teams must carefully evaluate factors such as after-sales service coverage, spare parts availability, and software localization (e.g., language support and integration with local PACS/RIS systems) to avoid operational disruptions.

When procuring a Chinese PET/CT system, B2B buyers should follow a structured approach: first, conduct a technical audit of the supplier’s quality management system and request evidence of regulatory approvals (CE, FDA, or local equivalents). Second, negotiate a service-level agreement (SLA) that includes remote diagnostics, on-site maintenance, and guaranteed response times—preferably with a local European partner. Third, assess total cost of ownership (TCO), including shipping, customs clearance, installation, and training costs. Key risks include supply chain delays, software incompatibility with existing hospital networks, and potential tariff changes. To mitigate these, consider engaging a third-party inspection agency (e.g., SGS or TÜV) for pre-shipment verification and ensure the supplier maintains a regional spare parts warehouse. Finally, prioritize suppliers that offer upgrade paths for AI algorithms and dose reduction technologies, as European regulators increasingly emphasize patient safety and radiation protection.

For logistics and installation, European buyers must account for customs clearance procedures under the EU’s Medical Device Regulation (MDR) and possible additional documentation for Chinese-origin equipment. Working with a freight forwarder experienced in medical device transport is advisable. Additionally, some Chinese manufacturers offer leasing or pay-per-scan models, which can lower upfront capital expenditure—a growing trend in procurement strategies. Always verify that the supplier provides training for radiologists and technicians on the specific system, as software interfaces may differ from Western counterparts. By aligning technical specifications with clinical needs and engaging in rigorous due diligence, B2B buyers can successfully integrate Chinese whole-body PET/CT systems into their European healthcare facilities, benefiting from innovation without compromising on quality or compliance.

Reposted for informational purposes only. Views are not ours. Stay tuned for more.